1Centers for Disease Control and Prevention. Laboratory-acquired West Nile virus infection-United States. 2002. MMWR, 2002,51:1133-1135. 被引量：1
2West Nile Virus: What you need 1o know. Available at http://www. cdc. gov/ ncidod/dvbid/wesmile/wnv_factSheeL htm. 被引量：1
3Solomon T, Ooi MH, Beasley DW. et at. West Nile encephalitis.BMJ, 2003,326 : 865-869. 被引量：1
4Guidelines for Surveillance, Prevemion and Control, Available at http ://www. cdc. gov/ncidod/dvbid/wesmile/lab_guidance, htm. 被引量：1
5Huhn GD, Sejvar J J, Montgomery SP, et al. West Nile virus in the United States: an update on an emerging infectious disease. Am Faro Phvsician 2003,68:653-660. 被引量：1
6Lanciotti RS, Kerst AJ, Nasci RS. et al. Rapid detection of West Nile virus from human clinical specimens, field-collected mosquitoes,and avian samples by a TaqMan reverse teanscriptase PCR assay. J Clin Microbiot. 2000, 38:4066-4071. 被引量：1
7Jordan 1, Briense T, Fischer N, et al. Ribavirin inhibits West Nile virus replication and cytopmhic effect in neural cell. J Infect Dis,2000, 182:1214-1217. 被引量：1
8Anderson JF, Rahal JJ. Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerg Infect Dis, 2002,6 : 107-108. 被引量：1
9Ben Nathan D, Lustig S, Tan G, et al. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J Infect Dis,2003,188 : 5- 12. 被引量：1
10A phase Ⅰ/Ⅱ randomized, placebo-controlled trial to assess the safety and efficacy of intravenous immunoglobulin G (Omr-IgG-am)containing high antl-West Nile virus antibody titers in patients with,or at high risk for progression to West Nile virus (WNV). Available http://www. clinicalt rials, gov/ct/show/ NCT00069316? Order-1. 被引量：1
